ProHance is a macrocyclic, nonionic, gadolinium-based magnetic resonance imaging (MRI) contrast agent designed for use in MRI in adults and children over two years of age to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. ProHance is also indicated for use in MRI in adults to visualize lesions in the head and neck.
The agent reportedly has the highest thermodynamic stability constant and lowest osmolality of all gadolinium contrast agents in its class.
The clinical experience with ProHance exceeds 10 million doses safely administered worldwide, according to the company.


Additional Content

News | Contrast Media

Oct. 27, 2026 – Bracco has announced plans to invest $230 million to establish its first U.S. manufacturing facility for ...

Time October 28, 2026
arrow
News | Cardiac Imaging

Aug. 11, 2026 — Bracco Imaging recently announced that VueJect, its dedicated ultrasound contrast delivery system ...

Time August 12, 2026
arrow
News | Contrast Agents

June 15, 2026 – Bayer has announced that the U.S. Food and Drug Administration (FDA) approved Ambelvist (gadoquatrane) ...

Time June 16, 2026
arrow
News | FDA

May 18, 2026 — ACIST Medical Systems, a Bracco company, has received U.S. Food and Drug Administration (FDA) clearance ...

Time May 18, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 4, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Bayer for the expanded ...

Time March 04, 2026
arrow
Subscribe Now